Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
JCR Pharmaceuticals Co., Ltd. ( (JP:4552) ) has provided an announcement.
JCR Pharmaceuticals revised its consolidated financial forecasts for the fiscal year ended March 31, 2025, reflecting a downward adjustment in net sales from 41,300 million yen to 39,000 million yen. This revision is primarily due to the non-conclusion of an overseas licensing agreement for JR-171 and increased costs in manufacturing and R&D expenses. Despite this, the company maintains its dividend forecast, indicating strategic stability amidst financial adjustments.
More about JCR Pharmaceuticals Co., Ltd.
JCR Pharmaceuticals Co., Ltd. is a global specialty pharmaceuticals company focused on developing therapies for rare and genetic diseases. With a 49-year legacy in Japan, the company is expanding its global presence in the US, Europe, and Latin America. JCR aims to improve patients’ lives through innovative therapies for conditions such as growth disorders, MPS II, Fabry disease, and renal anemia, along with investigational treatments for additional rare diseases.
YTD Price Performance: -6.10%
Average Trading Volume: 369,071
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: Yen70.54B
For a thorough assessment of 4552 stock, go to TipRanks’ Stock Analysis page.
